Topotecan
- Generic Name
- Topotecan
- Brand Names
- Hycamtin, Potactasol, Topotecan Hospira
- Drug Type
- Small Molecule
- Chemical Formula
- C23H23N3O5
- CAS Number
- 123948-87-8
- Unique Ingredient Identifier
- 7M7YKX2N15
- Background
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
- Indication
用于小细胞肺癌（SCLC）和一线治疗失败的晚期转移性卵巢癌。
- Associated Conditions
- Acute Myeloid Leukemia, Ewing's Sarcoma, Refractory Neuroblastoma, Metastatic Rhabdomyosarcoma, Recurrent Stage IVB Cervical Cancer, Refractory CNS lymphoma, Refractory CNS malignancy, Refractory, metastatic Ovarian cancer, Relapsed Platinum Sensitive Small Cell Lung Cancer (SCLC)
Berzosertib Human Mass Balance Study (DDRiver Solid Tumors 208)
- Conditions
- Advanced Solid Tumor
- Interventions
- First Posted Date
- 2022-02-18
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
- Target Recruit Count
- 6
- Registration Number
- NCT05246111
- Locations
- 🇭🇺
Magyar Honvédség Egészségügyi Központ, Podmaniczky utcai telephely, Onkológiai Osztály, Budapest, Hungary
🇭🇺PRA Magyarország Kft. Fázis I-es Klinikai Farmakológiai Vizsgálóhely, Budapest, Hungary
Clinical Trial of Lurbinectedin As Single-agent or in Combination with Irinotecan Versus Topotecan or Irinotecan in Patients with Relapsed Small-cell Lung Cancer (LAGOON)
- Conditions
- Relapsed Small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-12-10
- Last Posted Date
- 2025-01-30
- Lead Sponsor
- PharmaMar
- Target Recruit Count
- 705
- Registration Number
- NCT05153239
- Locations
- 🇩🇰
Vejle Hospital, Vejle, Denmark
🇫🇷Hopital Jean Minjoz, Besancon, France
🇫🇷AssAP-HP - Hopital Ambroise-Pare, Boulogne-Billancourt, France
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Conditions
- Acute Myeloid Leukemia
- Interventions
- First Posted Date
- 2021-11-01
- Last Posted Date
- 2025-04-23
- Lead Sponsor
- Jennifer Lauren Kamens
- Target Recruit Count
- 34
- Registration Number
- NCT05101551
- Locations
- 🇺🇸
Phoenix Children's Hospital, Phoenix, Arizona, United States
🇺🇸Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸City of Hope, Duarte, California, United States
Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)
- Conditions
- Platinum-resistant Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer
- Interventions
- Biological: PembrolizumabBiological: NemvaleukinBiological: Nemvaleukin and Pembrolizumab Combination
- First Posted Date
- 2021-10-25
- Last Posted Date
- 2024-06-28
- Lead Sponsor
- Mural Oncology, Inc
- Target Recruit Count
- 456
- Registration Number
- NCT05092360
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇪🇸Hospital Clinico Universitario de Valencia, Valencia, Spain
🇨🇳Taichung Veterans General Hospital, Taichung, Taiwan
Reducing Hypoxia in Patients With Coronavirus Disease (COVID-19) Using Topotecan With Standard of Care
- First Posted Date
- 2021-10-19
- Last Posted Date
- 2021-11-04
- Lead Sponsor
- National University Hospital, Singapore
- Target Recruit Count
- 24
- Registration Number
- NCT05083000
- Locations
- 🇮🇳
Christian Medical College, Vellore, Tamil Nadu, India
Intra-Arterial Chemotherapy for Newly Diagnosed, Residual, or Recurrent Atypical Choroid Plexus Papilloma and Choroid Plexus Carcinoma Prior to Second-Look Surgery
- Conditions
- Atypical Choroid Plexus PapillomaChoroid Plexus Carcinoma
- Interventions
- First Posted Date
- 2021-08-06
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- Weill Medical College of Cornell University
- Target Recruit Count
- 1
- Registration Number
- NCT04994977
- Locations
- 🇺🇸
Weill Cornell Medicine, New York, New York, United States
A Study of N9 Chemotherapy in Children With Neuroblastoma
- Conditions
- Pediatric CancerNeuroblastoma
- Interventions
- First Posted Date
- 2021-07-01
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 26
- Registration Number
- NCT04947501
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Balstilimab Versus Investigator Choice Chemotherapy in Patients With Recurrent Cervical Cancer (BRAVA)
- Conditions
- Metastatic Cervical CancerAdvanced Cancer
- Interventions
- First Posted Date
- 2021-06-29
- Last Posted Date
- 2022-10-05
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT04943627
- Locations
- 🇦🇲
Hematology Center after prof. R. Yeolyan, Yerevan, Armenia
🇦🇲National Center of Oncology named after V.A. Fanarjian, Yerevan, Armenia
🇺🇸Optimum Research (Southwest Women's Oncology Center), Albuquerque, New Mexico, United States
A Phase III Study of BD0801 Combined With Chemotherapy in Recurrent, Platinum-resistant Epithelial Ovarian Cancer
- Conditions
- Ovarian Cancer
- Interventions
- First Posted Date
- 2021-06-01
- Last Posted Date
- 2024-01-17
- Lead Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
- Target Recruit Count
- 421
- Registration Number
- NCT04908787
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Topotecan and Melphalan for Retinoblastoma
- Conditions
- RetinoblastomaChemotherapy Effect
- Interventions
- First Posted Date
- 2021-03-16
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 50
- Registration Number
- NCT04799002
- Locations
- 🇨🇳
Sun Yat-sen University, Guangzhou, Guangdong, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.